Combined anti-proliferative and anti-angiogenic strategies for cancer

Jair Bar, Amir Onn

Research output: Contribution to journalReview articlepeer-review


Background: In recent years, anti-angiogenic treatments have been shown to synergize with traditional chemotherapeutic and radiotherapeutic regimens. Combining anti-angiogenesis with targeted anti-proliferative agents might also be synergistic. Several lines of evidence point to the validity of this approach, and preliminary results of ongoing and recent studies support it. Objective: The background and current status of anti-angiogenic and anti-proliferative treatments will be summarized, as well as the evidence supporting and antagonizing their combined use in the clinic. Methods: Relevant literature was reviewed using PubMed search, and recent major conference proceedings and other relevant data were searched through internet publications. Results/conclusion: Combining anti-angiogenic and anti-proliferative treatments seems a promising approach, although not in all clinical circumstances.

Original languageEnglish
Pages (from-to)701-715
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Issue number5
StatePublished - Apr 2008


  • Angiogenesis
  • Bevacizumab
  • Cancer
  • Cetuximab
  • Chemotherapy
  • Erlitinib
  • Proliferation
  • Sorafenib
  • Sunitinib
  • Targeted treatments
  • Trastuzuamb
  • Vandetanib


Dive into the research topics of 'Combined anti-proliferative and anti-angiogenic strategies for cancer'. Together they form a unique fingerprint.

Cite this